Expression and prognostic value of drug resistance-associated markers P-gp, Mrp1, Mrp2 and Lrp in ovarian cancer;Espressione e significato progllostico dei markers di chemioresistenza P-gp, Mrp1, Mrp2 e Lrp nei carcinomi ovarici

Minerva Ginecologica

Volumn 51, Issue 12, 1999, Pages 463-470

  Katsaros, D ^a,b   Fracchioli, S ^a,b   Arts, H J G ^a,b   De Vries, E G E ^a,b   Danese, S ^a,b   Richiardi, G ^a,b   Arisio, R ^a,b   Gordini, G ^a,b   Van der Zee, A G J ^a,b   Suurmeijer, A J H ^a,b   Massobrio, M ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

Chemotherapy adjuvant; Drug resistance, multiple; Drug resistance, neoplasm; Lrp; Mrp; Ovarian neoplasms; P gp; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; ABC TRANSPORTER; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; RIBONUCLEOPROTEIN; TUMOR PROTEIN;

ANION TRANSPORT; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL FEATURE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOLOGY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE SECTION; TUMOR DIFFERENTIATION; BIOSYNTHESIS; DRUG RESISTANCE; GENE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; OVARY TUMOR; SURVIVAL RATE;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, MDR; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PROGNOSIS; SURVIVAL RATE; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0033237397     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S. Cancer statistics 1997. CA-Cancer. J Clin 1997;47:5.
2. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1.
3. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113
4. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993;71:644.
5. Van der Zee AGJ, Hollema HH, de Bruijn HW. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 1995;58:165.
6. Lehnert M. Clinical multidrug resistance in cancer: a nuiltifactorial problem. Eur J Cancer 1996;32A:912.
7. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945.
8. Granr CE, Valdimarsson G. Hipfner DR. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357.
9. Taniguchi K, Wada M, Kohno K. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996;56:4124.
10. Kool M, de Haas M, Scheffer GL. Analysis of expression of c-MOAT (Mrp2), Mrp2, Mrp4 and Mrp5, homologs of the multidrug resistance-associated protein gene (Mrp1), in human cancer cell lines. Cancer Res 1997;57:3537.
11. Keppler D, Leier I, Jedlitschky G. Transport of glutathion conjugates and glucuronides by the multidrug resistance proteins Mrp1 and Mrp2. J Biol Chem 1997;378:787.
12. Koike K, Kawabe T, Tanaka T. A canalacular multi-specific organic anion transporter (cMOAT) antisense CDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57:5475.
13. Evers R, Kool M, van Deemter L. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (Mrp2) cDNA. J Clin Invest 1998;101:1310.
14. Izquierdo MA, Shoemaker RH, Flens MJ. Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer 1996;65:230.
15. Scheffer GL, Wijngaard PL, Flens MJ. The drug resistance-related protein LRP is the human majior vault protein. Nature Med 1995;6:578.
16. Izquierdo MA, Van der Zee AGJ, Vermorken JB. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230.
17. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for cancer of the cervix and ovary. Am J Obstet Gynecol 1987;156:236.
18. Rubin SC. Chemotherapy of gynecologic cancer. In: Rubin SC, editor. Society of Gynecologic Oncologists Handbook. New York: Lippincot-Raven, 1996:187.
19. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors. Geneva: World Health Organization. 1973:17-8.
20. Sobre B, Frankendal B, Veress B. Importance of histological grade in the prognosis of epithelial ovarian carcinomas. Obstet Gynecol 1982;59:567.
21. Scheper RJ, Bulte JW, Brakkee JG. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int J Cancer 1988;42:389.
22. Flens MJ, Izquierdo MA, Sclieffer GI. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994;54:4563.
23. Scheper RJ, Broxterman HJ, Scheffer GL. Overexpression of a M(r) 110.000 vescicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475.
24. Paulusma CC, Bosnia PJ, Zaman GJR. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996;271:1126.
25. Van der Zee AGJ, Hollema HH, Suurmeijer AJ. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70.
26. Alberts DS, Taetle R, Frutiger E. Multidrug resistance expression as an independent risk factor for poor survival in optimal stage III ovarian cancer. Proc Am Soc Clin Oncol 1998;12:1356.
27. Rubin SC, Finstad CL, Hoskins WJ. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990;163:69.
28. Van der Zee AG, Hollema H, de Jong S. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991;51:5915.
29. Arao S, Suwa H, Mandai M. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 1994;54:1355.
30. Kavallaris M, Leary JA, Barrett JA. MDR1 and antidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 1996;102:7.
31. Broxterman HJ, Lankelma J, Pinedo HM. How to probw clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996; 32A:1024.
32. Kauffmann HM, Keppler D, Kartenbeck J. Induction of cMrp/cMOAT gene expression by cisplatin, 2-acetyla-minofluorene, or cycloheximide in rat hepatocytes. Hepatology 1997;26:980.